You are here: Industry Insights > NVX‑CoV2373

News List

Novavax expands deal with Serum Institute, aims for two billion COVID-19 vaccine doses expresspharma
September 16, 2020
Serum Institute will also manufacture the antigen component of the vaccine, dubbed NVX‑CoV2373.
Takeda to license Novavax’ Covid-19 vaccine candidate NVX‑CoV2373 pharmaceutical-business-review
August 12, 2020
Novavax has agreed to grant the Japanese licensing rights to NVX‑CoV2373, a vaccine candidate modified from the genetic sequence of the Covid-19 causing SARS‑CoV‑2 virus, to Takeda Pharmaceutical.
Novavax partners with Takeda to develop Covid-19 vaccine in Japan pharmaceutical-technology
August 11, 2020
US-based biotechnology firm Novavax has partnered with Takeda Pharmaceutical to develop, manufacture and commercialise its Covid-19 vaccine candidate, NVX‑CoV2373, in Japan.
Novavax and Serum Institute of India Announce Collaboration contractpharma
August 11, 2020
Serum Institute gains exclusive rights to commercialize in India and non-exclusive rights to commercialize in other LMIC countries.
Novavax presents positive data from Phase I COVID-19 vaccine trial europeanpharmaceuticalreview
August 07, 2020
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.
Novavax Awarded DoD Contract for COVID-19 Vaccine contractpharma
June 08, 2020
Agreement includes a 2020 delivery of 10 million doses of NVX‑CoV2373 for DoD for Phase II/III trials or under an EUA if approved by the FDA.
Novavax gets US defense funding for its COVID-19 vaccine expresspharma
June 05, 2020
The US-based company said the deal includes the delivery of 10 million doses of its COVID-19 vaccine - NVX‑CoV2373 - to the DoD this year.
Novavax buys Praha Vaccines for Covid-19 vaccine manufacturing pharmaceutical-technology
May 29, 2020
Biotechnology firm Novavax has acquired Czech Republic-based Praha Vaccines for approximately $167m to support the manufacture of its Covid-19 vaccine candidate, NVX‑CoV2373.
Novavax Expands Large-Scale Global Manufacturing Capacity contractpharma
May 28, 2020
Acquires Praha Vaccines in Czech Republic; annual operating capacity of over 1 billion doses of COVID-19 vaccine antigen.